Background:
Cameroon and Kenya currently use a SARS-CoV-2 ‘screen and test’ (ST) model, offering testing if clients have COVID-19-like symptoms or were exposed. In a randomized control trial comparing two testing models, the test-all (TA) model (testing offered regardless of screening outcome) identified more SARS-CoV-2 positive cases than the ST model. It is important to determine costs and cost-effectiveness associated with implementation of the TA model compared to the ST model prior to expansion.
Methods:
The total costs of implementing TA and ST in Cameroon and Kenya were estimated from a health systems perspective using a micro-costing method. The cost per client tested (PCT) and tested positive (PCTP) were estimated by dividing the total cost of each model by the number of clients tested and tested positive, respectively. A decision tree designed in TreeAge and cost-effectiveness acceptability curve were used to compare the cost-effectiveness of the two models. One-way sensitivity and probabilistic sensitivity analyses were used to assess the effect of uncertainties in key parameters on costs per client and cost-effectiveness, respectively.
Results:
In Cameroon, the total cost of TA was $141,942 and ST was $48,020. In TA model, the cost PCT was US$8 and the PCTP for SARS-CoV-2 was $509, whereas in the ST model the cost PCT was $25 and the cost PCTP was $728. The biggest expenditure in the TA model was SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDT), 61% ($86,853), and for ST was personnel, 39% ($18,592). In Kenya, the total cost of TA was $39,264 and for ST was $27,500. In the TA model the cost PCT for SARS-CoV-2 was $13 and PCTP was $1,190, whereas in the ST model the cost PCT for SARS-CoV-2 was $125 and PCTP was $1,250. In both models in Kenya, the biggest expenditure was personnel, which corresponded to 45% ($17,696) in TA and 56% ($15,267) in the ST model. In both countries, TA model was more cost-effective.
Conclusions:
With the current global efforts to lower the price of SARS-CoV-2 Ag-RDT, TA model is likely to be more cost-effective. The widespread implementation of TA model, as done in this project, would help identify priority areas for vaccination and individuals with SARS-CoV-2 infection early for treatment/quarantine. When budgeting for expansion of TA model, the estimated population size, costs of SARS-CoV-2 Ag-RDT, and personnel must be accurate, since they were shown in the sensitivity analysis to have the biggest impact on costs per client and cost-effectiveness.